0001209191-14-002646.txt : 20140109 0001209191-14-002646.hdr.sgml : 20140109 20140109164915 ACCESSION NUMBER: 0001209191-14-002646 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20140107 FILED AS OF DATE: 20140109 DATE AS OF CHANGE: 20140109 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: SALIX PHARMACEUTICALS LTD CENTRAL INDEX KEY: 0001009356 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 943267443 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 8510 COLONNADE CENTER DRIVE CITY: RALEIGH STATE: NC ZIP: 27615 BUSINESS PHONE: (919) 862-1000 MAIL ADDRESS: STREET 1: 8510 COLONNADE CENTER DRIVE CITY: RALEIGH STATE: NC ZIP: 27615 FORMER COMPANY: FORMER CONFORMED NAME: SALIX HOLDINGS LTD DATE OF NAME CHANGE: 19970807 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: KEANE WILLIAM P CENTRAL INDEX KEY: 0001204286 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-23265 FILM NUMBER: 14519257 MAIL ADDRESS: STREET 1: C/O SALIX PHARMACEUTICALS, LTD. STREET 2: 8510 COLONNADE CENTER DRIVE CITY: RALEIGH STATE: NC ZIP: 27615 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2014-01-07 0 0001009356 SALIX PHARMACEUTICALS LTD SLXP 0001204286 KEANE WILLIAM P 8510 COLONNADE CENTER DRIVE RALEIGH NC 27615 1 0 0 0 Common Stock 2014-01-07 4 M 0 22500 18.8733 A 57740 D Common Stock 2014-01-07 4 S 0 22500 88.31 D 35240 D Option to Buy Common Stock 18.8733 2014-01-07 4 M 0 22500 0.00 D 2014-06-17 Common Stock 22500 0 D Option to Buy Common Stock 17.63 2015-06-09 Common Stock 15000 15000 D The exercise and sale were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2013. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $87.93 to $88.88, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Options are 100% vested. /s/ William P. Keane 2014-01-09